Speakers: Jonathan Davila PhD., CEO / Co-Founder, NeuCyte Inc.
Organizers:
Date: 2017-07-28
Time: 11:00-13:30 Pacific Time
Registration fee: (USD): Food: $0.
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Cellular Dynamics Intl
Vendor show vendors registered to date: (5)Agilent; BioLegend; Cyprotex; JL Powers & Co; Thermo Fisher Scientific, SID
Registration: http://www.PBSS.org
Registration deadline:2017-07-26  (it will close sooner if the seating cap is reached)

About the Topic

High attrition rates of novel CNS drugs indicate that current preclinical testing is largely insufficient to support development of urgently needed therapies for millions of patients. iPSC technology and rapidly improving methods to generate functional human tissues offer new opportunities to develop novel disease relevant cell-based assays. This approach comes with high expectations but also presents many challenges. NeuCyte develops human neural in vitro platforms uniquely suited for assessing relevant complex  electrophysiology readouts allowing for more reliable prediction of drug efficacy, CNS safety, and identification of neurotoxicity. In this presentation, we will provide an overview of critical considerations that need to be taken when developing human iPSC derived neural in vitro assays.